Cambridge Investment Research Advisors
CRBP icon

Cambridge Investment Research Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,682
Closed -$393K – 3431
2024
Q2 		$393K Sell
8,682
-500
-5% -$21K ﹤0.01% 2482
2024
Q1 		$360K Buy
+9,182
New +$226K ﹤0.01% 2557
2023
Q1 		– Sell
-2,225
Closed -$7K – 3172
2022
Q4 		$7K Sell
2,225
-236
-10% -$908 ﹤0.01% 3082
2022
Q3 		$12K Buy
2,461
+14
+0.6% +$99 ﹤0.01% 3018
2022
Q2 		$19K Sell
2,447
-34
-1% -$329 ﹤0.01% 3001
2022
Q1 		$40K Sell
2,481
-1,383
-36% -$18.3K ﹤0.01% 3092
2021
Q4 		$71K Buy
3,864
+833
+27% +$22.6K ﹤0.01% 3067
2021
Q3 		$93K Buy
3,031
+6
+0.2% +$237 ﹤0.01% 2963
2021
Q2 		$166K Buy
3,025
+35
+1% +$1.94K ﹤0.01% 2881
2021
Q1 		$177K Sell
2,990
-312
-9% -$20.5K ﹤0.01% 2665
2020
Q4 		$124K Sell
3,302
-643
-16% -$24K ﹤0.01% 2569
2020
Q3 		$213K Buy
3,945
+1,748
+80% +$317K ﹤0.01% 2194
2020
Q2 		$553K Buy
2,197
+594
+37% +$120K ﹤0.01% 1495
2020
Q1 		$252K Sell
1,603
-22
-1% -$3.72K ﹤0.01% 1778
2019
Q4 		$266K Sell
1,625
-26
-2% -$3.84K ﹤0.01% 1986
2019
Q3 		$241K Buy
1,651
+35
+2% +$6.1K ﹤0.01% 1984
2019
Q2 		$336K Buy
1,616
+7
+0.4% +$1.5K ﹤0.01% 1680
2019
Q1 		$336K Buy
1,609
+25
+2% +$5.51K ﹤0.01% 1740
2018
Q4 		$278K Buy
1,584
+388
+32% +$77.4K ﹤0.01% 1709
2018
Q3 		$271K Buy
1,196
+413
+53% +$66.8K ﹤0.01% 1861
2018
Q2 		$119K Sell
783
-415
-35% -$75.4K ﹤0.01% 2091
2018
Q1 		$219K Buy
1,198
+301
+34% +$67.6K ﹤0.01% 1907
2017
Q4 		$191K Buy
897
+10
+1% +$2.14K ﹤0.01% 1943
2017
Q3 		$190K Buy
+887
New +$174K ﹤0.01% 1839

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Cambridge Investment Research Advisors's CRBP Position: Q3 2024 in Review

Cambridge Investment Research Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q3 2024, closing a stake of 8,682 shares — an estimated $393K sold.

Cambridge Investment Research Advisors first reported a position in CRBP in Q3 2017 and held it in 24 quarters. The position peaked at $553K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • Cambridge Investment Research Advisors reported no remaining Corbus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 8,682 Corbus Pharmaceuticals shares in Q3 2024, an estimated $393K.
  • Cambridge Investment Research Advisors first reported a position in Corbus Pharmaceuticals in Q3 2017 and held it in 24 quarters.
  • Cambridge Investment Research Advisors's Corbus Pharmaceuticals position peaked at $553K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2024, filed 28 Oct 2024.